Lamictal Buyers Urge 3rd Circ. To Revive Pay-For-Delay Case
Drug purchasers challenging a no-authorized-generic settlement between GlaxoSmithKline PLC and Teva Pharmaceutical Industries ltd. told the Third Circuit on Friday that the U.S. Supreme Court's recent pay-for-delay ruling didn't create a...To view the full article, register now.
Already a subscriber? Click here to view full article